newsfilter
← Latest News
Business Wire·

Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference

Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini